ClinicalTrials.gg
Active, not recruitingNCT05893420Updated Jul 29, 2025

A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning

An interventional study of eCARTv5 clinical deterioration monitoring and Standard of care control in Sepsis, Septicemia and Respiratory Failure, sponsored by AgileMD, Inc.. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by AgileMD, Inc. · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30,000
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 517 studies in Sepsis with a site in United States — 74 open to participants now, 99 under way, 3 of them phase 3. Sepsis · United States.

Planned enrollment
7th of 310
30,000 · median 84
Started
2024
with 21 others
No phase
140 of 517
22 open now
Primary completion
2026-12
later than 27 of 98 live
Registered
434th of 517
by date

Among the 517 studies in Sepsis with a site in United States, this one is the 7th largest by planned enrollment of the 310 interventional ones that give a count, is one of 22 that started in 2024, is one of 140 with no phase, reaches primary completion later than 27 of the 98 other live ones, and was the 434th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

74 of the 517 studies in Sepsis with a site in United States are open now. Recruiting first, the newest first:

69 more — sign in →

All 74 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 517 studies in Sepsis with a site in United States, or all of them as a file.
02

Study summary

In this study, the investigators will deploy a software-based clinical decision support tool (eCARTv5) into the electronic health record (EHR) workflow of multiple hospital wards. eCART's algorithm is designed to analyze real-time EHR data, such as vitals and laboratory results, to identify which patients are at increased risk for clinical deterioration. The algorithm specifically predicts imminent death or the need for intensive care unit (ICU) transfer. Within the eCART interface, clinical teams are then directed toward standardized guidance to determine next steps in care for elevated-risk patients.

The investigators hypothesize that implementing such a tool will be associated with a decrease in ventilator utilization, length of stay, and mortality for high-risk hospitalized adults.

Read the detailed description

The objective of this proposal is to rapidly deploy a clinical decision support tool (eCARTv5) within the electronic health record of multiple medical-surgical units. eCART combines a real-time machine learning algorithm for identifying patients at increased risk for intensive care (ICU) transfer and death with clinical pathways to standardize the care of these patients based on a real-time, quantitative assessment of patient risk.

The investigators hypothesize that implementing such a tool will be associated with a decrease in ventilator utilization, length of stay, and mortality for high-risk hospitalized adults.

Background:

Clinical deterioration occurs in approximately 5% of hospitalized adults. Delays in recognition of deterioration heighten the risk of adverse outcomes. Machine learning algorithms enhance clinical decision-making and can improve the quality of patient care. However, their impact on clinical outcomes depends not only on the sensitivity and specificity of the algorithm but also on how well that algorithm is integrated into provider workflows and facilitates timely and appropriate intervention.

Preliminary Data:

eCART has been built upon more than a decade of ongoing scientific research and chronicled in numerous peer-reviewed publications. eCART was developed at the University of Chicago by Drs. Dana Edelson and Matthew Churpek. The first version (eCARTv1) was derived and validated using linear logistic regression in a dataset of nearly 60,000 adult ward patients from a single medical center. That model had 16 variables in it and was subsequently validated in silent mode, demonstrating that eCART could alert clinicians more than 24 hours in advance of ICU transfer or cardiac arrest. eCARTv2, derived and validated in a dataset of nearly 270,000 patients from 5 hospitals, improved upon the earlier version by utilizing a cubic spline logistic regression model with 27 variables and demonstrated improved accuracy over the Modified Early Warning Score (MEWS), a commonly used score that can be hand- calculated by nurses at the bedside (AUC 0.77 vs. 0.70 for cardiac arrest, ICU transfer or death). In a multicenter clinical implementation study, eCARTv2 was associated with a 29% relative risk reduction for mortality. In further development of eCART, the University of Chicago research team demonstrated that upgrading from a cubic spline model to a machine learning model, such as a random forest or gradient boosted machine (GBM), could increase the AUC. In the most recent development - eCART v5 - the research team has advanced the analytic using a gradient boosted machine learning model trained on a multi-center dataset of more than 800,000 patient records. Now with 97 variables, this more sophisticated model increases the accuracy by which clinicians can predict clinical deterioration.

03

Conditions studied

  • Sepsis
  • Septicemia
  • Respiratory Failure
  • Hemodynamic Instability
  • COVID-19
  • Cardiac Arrest
  • Clinical Deterioration

Keywords

  • machine learning
  • artificial intelligence
  • early warning scores
  • clinical decision support
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old
  • Admitted to an eCART-monitored medical-surgical unit (scoring location)

Exclusion criteria

Exclusion Criteria:

  • Younger than 18 years old
  • Not admitted to an eCART-monitored medical surgical unit (scoring location)
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
30,000 participants (estimated)

Study arms

  • Experimental
    Intervention Arm

    Intervention Arm (experimental): eCARTv5 will monitor all adult medical-surgical (ward) patients at hospitals that implement the tool in their EHR. A pre vs. post analysis will be done to compare the impact of the tool at the intervention hospitals.

    Device: eCARTv5 clinical deterioration monitoring

  • Active comparator
    Control Arm

    Control Arm (active comparator): hospital sites that do not implement eCARTv5 will be active comparator.

    Other: Standard of care control

Interventions

  • DeviceeCARTv5 clinical deterioration monitoring

    eCART is a predictive analytic used for the identification of acute clinical deterioration built upon more than a decade of ongoing scientific research and chronicled in numerous peer-reviewed publications. eCART draws upon readily available patient data from the EHR, rapidly quantifies disease severity, and predicts the likelihood of critical illness onset.

  • OtherStandard of care control

    Standard of care is the health system's clinical best practices and workflows for identifying high-risk patients for clinical deterioration, including other tools already built into the electronic health record (EHR). Hospitals that do not implement eCARTv5 will be compared as a control against hospitals that do implement eCARTv5.

06

What researchers measure

Primary outcomes

  1. Hospital mortality for elevated risk patients

    Hospital mortality, a measure of how many patients died in the hospital, will come from administrative data, specifically from the discharge disposition of each eCART elevated risk patient. This data will be taken from the complete hospitalization, from admission to discharge.

    Time frame: The outcome of hospital mortality for elevated risk patients will be tracked across 12 months

Secondary outcomes

  1. Total hospital length of stay (LOS) for elevated risk patients

    Total hospital length of stay (LOS) for patients with any elevated eCART score during hospitalization, defined as the time period between hospital admission and discharge. LOS is defined as the time (hours or fraction of a day) from first vital sign to last vital sign within a patient encounter.

    Time frame: Total hospital length of stay (LOS) for elevated risk patients will be tracked across 12 months

  2. ICU-free days following an eCART elevation

    30-day ICU-free days, defined as the number of days patients were both alive and not being cared for in an ICU in the first 30 days following hospital admission with any elevated eCART score. Because death is biased toward fewer ICU days and is a competing outcome, patients who die prior to day 30 are assigned with 0 ICU-free days.

    Time frame: The outcome of 30-day ICU-free days will be tracked across 12 months

  3. Ventilator-free days following an eCART elevation

    30-day ventilator-free days, defined as the number of days patients were both alive and not mechanically ventilated in the first 30 days following hospital admission with any elevated eCART score. Because death is biased toward fewer ventilator days and is a competing outcome, patients who die prior to day 30 are assigned with 0 ventilator-free days.

    Time frame: The outcome of 30-day ventilator-free days will be tracked across 12 months

Other outcomes

  1. Sepsis Mortality

    Hospital mortality, a measure of how many patients died in the hospital, will come from administrative data, specifically from the discharge disposition of each eCART elevated risk patient meeting Sep-1 criteria for sepsis.

    Time frame: The outcome of sepsis mortality will be tracked across 12 months

  2. Sepsis Length of Stay (LOS)

    Total hospital length of stay (LOS) for patients with any elevated eCART score during hospitalization that met Sep-1 criteria for sepsis.

    Time frame: The outcome of sepsis length of stay (LOS) will be tracked across 12 months

  3. COVID-19 Mortality

    Hospital mortality, a measure of how many patients died in the hospital, will come from administrative data, specifically from the discharge disposition of each eCART elevated risk patient with a COVID-19 diagnosis or positive COVID-19 test result.

    Time frame: The outcome of COVID-19 mortality will be tracked across 12 months

  4. COVID-19 Length of Stay (LOS)

    Total hospital length of stay (LOS) for patients with any elevated eCART score during hospitalization with a COVID-19 diagnosis or positive COVID-19 test result.

    Time frame: The outcomes of COVID-19 length of stay (LOS) will be tracked across 12 months

07

Study locations

3 sites
08

References and documents

Publications

  • Churpek MM, Yuen TC, Park SY, Meltzer DO, Hall JB, Edelson DP. Derivation of a cardiac arrest prediction model using ward vital signs*. Crit Care Med. 2012 Jul;40(7):2102-8. doi: 10.1097/CCM.0b013e318250aa5a. PubMed 22584764 ↗
  • Churpek MM, Yuen TC, Winslow C, Robicsek AA, Meltzer DO, Gibbons RD, Edelson DP. Multicenter development and validation of a risk stratification tool for ward patients. Am J Respir Crit Care Med. 2014 Sep 15;190(6):649-55. doi: 10.1164/rccm.201406-1022OC. PubMed 25089847 ↗
  • Kang MA, Churpek MM, Zadravecz FJ, Adhikari R, Twu NM, Edelson DP. Real-Time Risk Prediction on the Wards: A Feasibility Study. Crit Care Med. 2016 Aug;44(8):1468-73. doi: 10.1097/CCM.0000000000001716. PubMed 27075140 ↗
  • Winslow CJ, Edelson DP, Churpek MM, Taneja M, Shah NS, Datta A, Wang CH, Ravichandran U, McNulty P, Kharasch M, Halasyamani LK. The Impact of a Machine Learning Early Warning Score on Hospital Mortality: A Multicenter Clinical Intervention Trial. Crit Care Med. 2022 Sep 1;50(9):1339-1347. doi: 10.1097/CCM.0000000000005492. Epub 2022 Aug 15. PubMed 35452010 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.

Of 326 interventional studies with no phase under Sepsis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2023
First posted
Jun 7, 2023
StartActual
Dec 31, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05893420
Lead sponsor
AgileMD, Inc.
Collaborators
Biomedical Advanced Research and Development Authority, University of Chicago, BayCare Health System, University of Wisconsin, Madison, Yale University
Responsible party
Sponsor
First posted
Jun 7, 2023
Start date
Dec 31, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 29, 2025

Study contacts

Dana P Edelson, MD, MS
study chair · AgileMD, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion